Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must:~* have been diagnosed with acute rhinosinusitis~* have had signs and symptoms of rhinosinusitis for at least 7 but not more than 28 days prior to Baseline~* have had a major symptom score \>=5 and \<=12 at the Screening and Baseline, and no more than 3 of the 5 major individual symptoms were to be rated as severe~* be \>=12 years old~* be in good health overall and normal laboratory tests~* not be pregnant, intending to become pregnant or intending to impregnate.~Exclusion Criteria:~Subjects who:~* have a history of chronic rhinosinusitis or who had undergone sinus or nasal surgery for chronic rhinosinusitis in the 6 months prior to Screening~* have fever \>=101°F and/or persistent severe unilateral facial pain/tooth pain; and/or orbital or peri-orbital facial swelling; and/or dental involvement; and/or worsening symptoms after initial improvement~* have a history of symptomatic seasonal allergic rhinitis who were exposed to allergenic pollens~* have asthma with FEV1\<65% of predicted volume in the past 3 months or who have had an exacerbation within the past 30 days~* have nasal polyps, Kartagener's syndrome, and otitis or atrophic rhinitis~* have certain comorbid conditions or contraindications to certain drug therapies

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): MFNS once daily
- 2 (Type: EXPERIMENTAL): MFNS twice daily
- 3 (Type: ACTIVE_COMPARATOR): Amoxicillin
- 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).